Anticipation for September MN-001 Phase 2 topline data fuels MNOV surge

 

Anticipation for September MN-001 Phase 2 topline data fuels 21% MNOV surge

• MediciNova highlighted imminent MN-001 (tipelukast) Phase 2 topline readout in NAFLD/hypertriglyceridemia/T2DM during H.C. Wainwright conference (Sept 14-16, 2026).
• Presentation and Sept 15 after-close update reaffirmed data expected by end of September (end Q3), per Japanese market reports.
• Builds on May 2026 LPLV completion; co-primary endpoints are liver fat (CAP score) and fasting triglycerides at 24 weeks.
• Prior open-label data showed strong triglyceride reductions; analysts maintain Strong Buy with ~$9 targets.
• Low-float biotech sees momentum buying and elevated volume amid near-term binary catalyst; up over 70% past month.
• Company holds ~$25M cash runway into key readouts, with COMBAT-ALS data also expected by year-end.

https://finviz.com/stock?t=MNOV&p=d